Titan Pharmaceuticals (FRA:TN70) Change In Receivables : €0.81 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals Change In Receivables?

Titan Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was €0.84 Mil. It means Titan Pharmaceuticals's Accounts Receivable declined by €0.84 Mil from Dec. 2023 to Mar. 2024 .

Titan Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was €-0.01 Mil. It means Titan Pharmaceuticals's Accounts Receivable increased by €0.01 Mil from Dec. 2022 to Dec. 2023 .

Titan Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Titan Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was €5.24 Mil.

Titan Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Titan Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Change In Receivables Chart

Titan Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.76

0.15

0.68

0.07

-0.01

Titan Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.02	-	-0.02	-0.01	0.84

Titan Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.81 Mil.

Titan Pharmaceuticals (FRA:TN70) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Titan Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.123	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Titan Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Titan Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.666	-	0.514	+	0.75 * 0.123	+	0.5 * 0
=	5.24

Titan Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (FRA:TN70) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TTNP:USA

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines